MolMed S.p.A.
MILAN : MLM

MolMed S.p.A.

May 17, 2012 01:00 ET

MolMed Clinical Development Update: Six Abstracts Accepted for Presentation at ASCO 2012

MILAN, ITALY--(Marketwire - May 17, 2012) - MolMed S.p.A. (MILAN:MLM) today announced that six abstracts featuring its investigational therapeutics NGR-hTNF and TK have been accepted for presentation at the 48th ASCO Annual Meeting, that will take place in Chicago (IL, USA) from June 1-5, 2012. The abstracts are now available on the ASCO 2012 website (http://chicago2012.asco.org).

Claudio Bordignon, MolMed's Chairman and CEO, comments: "This year yet again we had an important number of abstracts accepted at ASCO, including the concept and design of our ongoing cell therapy Phase III trial with TK. This confirms the quality and depth of our clinical development programme. For NGR-hTNF, the new data that will be presented at ASCO include first overall survival data of an ongoing randomised Phase II trial in lung cancer (NSCLC) and long-term follow-up data for several completed trials, including Phase II in mesothelioma".

Professor Bordignon added: "The double-blind Phase III trial of NGR-hTNF currently ongoing in mesothelioma doesn't allow interim analyses; however, I would like to stress that enrolment is progressing well, with over 200 patients recruited to date, representing more than half of the trial population. Primary analysis is expected in 2013."

Abstracts accepted at ASCO include the rationale of the TK add-back strategy to haploidentical bone marrow transplant and design of the ongoing Phase III trial of TK in adult patients affected by high-risk leukaemia. For NGR-hTNF, they include interim results of a randomised Phase II trial of NGR-hTNF in combination with cisplatin-based chemotherapy for non-small cell lung cancer, and long-term follow up data of completed Phase II trials in mesothelioma, ovarian cancer and small-cell lung cancer, as well as results of a Phase I trial at high doses. New data disclosed at ASCO will be announced in a separate press release during the meeting.

Presentation schedule at ASCO 2012

Abstract # Abstract title Poster exhibition date & time (CDT)
7076 NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM) Saturday 2 June, 1:15-5:15 PM
7085 NGR-hTNF and doxorubicin in relapsed small-cell lung cancer (SCLC) Saturday 2 June, 1:15-5:15 PM
7581 NGR-hTNF plus chemotherapy as first line therapy of non-small cell lung cancer (NSCLC) Saturday 2 June, 1:15-5:15 PM
5059 NGR-hTNF and doxorubicin in relapsed ovarian cancer (OC) Sunday 3 June, 8:00-12:00 AM
2580 Phase I safety, pharmacokinetic and pharmacodynamic trial of NGR-hTNF given at high doses in patients with refractory solid tumours Monday 4 June, 8:00-12:00 AM
6541 Randomised Phase III trial of haploidentical HCT with or without an add-back strategy of HSV-TK donor lymphocytes in patients with high-risk acute leukaemia Monday 4 June, 1:15-5:15 PM

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent (VTA), in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the Milan Stock Exchange, at the Standard segment (class I) of the MTA managed by Borsa Italiana. (Ticker Reuters: MLMD.MI).

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.

Contact Information